Currently, the efficacy of these agents is evaluated in clinical trials: CD33‐directed bi‐specific antibodies examined in the AML context, are, among others, the CD33/CD3 antibody constructs AMG330 and AMG673, the tetravalent CD33/CD3 tandem‐diabody AMV564, and the humanized single‐chain bi‐specific CD33/CD3 construct GEM333.48, 82, 103, 104, 105. The gene discussed is CD33; the disease is acute myeloid leukemia.